Neuronetics, Inc. (STIM)
| Market Cap | 115.17M -58.7% |
| Revenue (ttm) | 151.64M +69.5% |
| Net Income | -37.11M |
| EPS | -0.55 |
| Shares Out | 69.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,989,319 |
| Open | 1.840 |
| Previous Close | 1.840 |
| Day's Range | 1.640 - 1.840 |
| 52-Week Range | 0.800 - 4.850 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+81.27%) |
| Earnings Date | May 5, 2026 |
About STIM
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company... [Read more]
Financial Performance
In 2025, Neuronetics's revenue was $149.16 million, an increase of 99.17% compared to the previous year's $74.89 million. Losses were -$39.00 million, -10.78% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for STIM stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Neuronetics reports Q1 EPS (16c), consensus (17c)
Reports Q1 revenue $34.45M, consensus $34.18M. “I’m encouraged by our first quarter performance, which reflects the team’s continued execution on revenue growth, operational efficiency, and cash manag...
Neuronetics backs FY26 revenue view $160M-$166M, consensus $162.47M
Sees Q2 revenue up mid-single digits.
Neuronetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 8% year-over-year to $34.5 million, with improved net loss and adjusted EBITDA. Clinic revenue rose 15% on strong SPRAVATO growth, while NeuroStar system sales increased but treatment revenue declined. Guidance and cash outlook remain stable.
Neuronetics Reports First Quarter 2026 Financial and Operating Results
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company w...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t...
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve th...
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 St...
Neuronetics backs FY26 revenue view $160M-$166M, consensus $162.47M
Backs FY26 gross margin view 47%-49%. Backs FY26 operating expenses $100M-$105M. Backs FY26 operating cash flow view loss of $13M-$17M.
Neuronetics CFO Steven Pfanstiel to depart
Neuronetics (STIM) announced that Steven Pfanstiel will depart his role as executive VP, CFO, and treasurer to pursue an opportunity outside the company. He will remain with the company through
Neuronetics backs Q1 revenue view $33M-$35M, consensus $34.18M
The company said, “In conjunction with today’s announcement, Neuronetics (STIM) reaffirmed the financial guidance it provided during its fourth quarter 2025 earnings call on March 17, 2026.” Published...
Neuronetics’ largest independent shareholder urges review of alternatives
Jorey Chernett, the largest independent shareholder of Neuronetics (STIM), owning approximately 14.12% of outstanding shares, delivered a letter to the STIM Board of Directors calling for the immediat...
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business BLOOMFIELD HILLS, Mich., April 6, 2026 /PRNewswire/ -- Jorey Chern...
Neuronetics price target lowered to $3 from $7 at Canaccord
Canaccord lowered the firm’s price target on Neuronetics (STIM) to $3 from $7 and keeps a Buy rating on the shares. The firm said Q4 results and guidance are in
Neuronetics files to sell 20.74M shares of common stock for holders
16:56 EDT Neuronetics (STIM) files to sell 20.74M shares of common stock for holders
Neuronetics Earnings Call Transcript: Q4 2025
Q4 2025 saw 23% adjusted pro forma revenue growth and positive operating cash flow, driven by Greenbrook integration and strong clinic and NeuroStar performance. 2026 guidance projects >9% revenue growth, continued clinic expansion, and new therapy launches, with a focus on efficiency and profitability.
Neuronetics reports Q4 EPS (10c) vs. (34c) last year
Reports Q4 revenue $41.8M vs. $22.5M last year. “A year ago, we set out to build a vertically integrated mental health company, and I am proud of what this team
Neuronetics sees Q1 revenue $33M-$35M, consensus $37.22M
07:53 EDT Neuronetics (STIM) sees Q1 revenue $33M-$35M, consensus $37.22M
Neuronetics sees FY26 revenue $160M-$166M, consensus $164.15M
Gross Margin: 47% to 49%; Operating Expenses: $100 million to $105 million, inclusive of approximately $8.5 million of non-cash stock-based compensation; Operating Cash Flow: $(13) million to $(17) mi...
Neuronetics appoints Dan Reuvers as President and CEO
Neuronetics (STIM) appointed Dan Reuvers as the company’s next President and CEO, effective March 23. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan,
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% o...
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies Seas...
Neuronetics reports preliminary Q4 revenue $41.8M, consensus $40.66M
During the fourth quarter, the company drove positive operating cash flow of $0.9M, in line with previously issued guidance. “We wrapped up 2025 with strong commercial execution during the fourth
Neuronetics sees FY25 revenue $149.2M, consensus $148.08M
The company ended 2025 with $34.1M of total cash, inclusive of cash, cash equivalents and restricted cash.
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth o...
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company ...